EWING, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS)  a pharmaceutical technology company, today announced it will release its third quarter 2020 financial and operating results on Thursday, November 5, 2020, before the market opens.

Antares will host a conference call on Thursday, November 5, 2020 at 8:30am ET to discuss the results. The dial-in numbers are (888) 204-4368 for domestic callers and (323) 994-2093 for international callers. The conference ID number is 6925216. A live webcast and replay of the conference call will be available online from the investor relations section of the Antares Pharma corporate website at www.antarespharma.com.

About Antares Pharma

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s FDA-approved products include XYOSTED^® (testosterone enanthate) injection, OTREXUP^® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA^® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.